Brief: TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
14/01/2025 13:16
Jan 14 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
THIRD
COHORT WITH LEAD CANDIDATE IN PHASE 1 CLINICAL TRIAL
* TRANSCODE THERAPEUTICS INC - NO SIGNIFICANT SAFETY OR DOSE
LIMITING TOXICITIES IN COHORTS 1 AND 2
Source text: ID:nPn3t92lZa
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors